期刊文献+

TGFα、EGFR反义寡聚核苷酸对大肠癌生长的抑制作用 被引量:2

GROWTH INHIBITION OF COLORECTAL CANCER BY TGF-α ANTISENSE OLIGODEOXYNUCLEOTIDE AND EGFR ANTISENSE OLIGODEOXYNUCLEOTIDE
下载PDF
导出
摘要 研究转化生长因子α(TGFα)、表皮生长因子受体 (EGFR)反义寡聚核苷酸 (ASODN)对人大肠癌生长增殖的作用。反义TGFα、反义EGFR及无关对照ODN经阳离子脂质体包裹后转染人大肠癌HR8348细胞。采用噻唑蓝比色法 (MTT法 ) ,细胞周期分析 ,裸鼠体内接种等方法测定瘤细胞体内外增殖的变化。与对照组HR8348细胞相比 ,经TGFα反义ODN处理的HR8348细胞体外增殖速度减慢 (抑制率达 80 % )、DNA合成受抑、裸鼠体内成瘤率下降 (2 5 %∶ 10 0 % )。经EGFR反义ODN处理的HR8348细胞也得到了类似的结果。TGFα反义ODN、EGFR反义ODN均能有效抑制大肠癌细胞的体内外生长增殖。 To investigate the effects of TGFαantisense oligodexynucleotides(ASODN) and EGFR ASODN on human rectal carcinoma cell line HR8348. Cationic liposome, lipofectamine, were selected as delivery vector HR8348 cells were treated with ASODN in vitro. HR8348 cells with or without pretreatment were inoculated into nude mice. The proliferation and DNA synthesis of HR8348 cells treated with TGF-α ASODN and EGFR ASODN were greatly inhibited, and tumorigenic rate was also greatly reduced. TGF-α ASODN and EGFR ASODN could inhibit the proliferation of human colon cancer cell line in vitro as well as in vivo, the results implicate. The potential value in colorectal cancer gene therapy.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2000年第6期405-408,共4页 Medical Journal of Chinese People's Liberation Army
关键词 TGFΑ EGFR 大肠癌 ASODN 细胞增殖 transforming growth factor α epidermal growth factor receptor antisense colorectal neoplasm@
  • 相关文献

参考文献4

  • 1张宗显 许沈华 等.人直肠癌细胞系-HR8348的建立和生物学特性[J].中国科学:B辑,1986,(11):1197-1197.
  • 2司徒镇强,细胞培养,1996年,193页
  • 3Huang S,Int J Cancer,1992年,52卷,7期,978页
  • 4张宗显,中国科学.B,1986年,16卷,11期,1197页

共引文献2

同被引文献18

  • 1陈小东,梁启廉,李建文,王三明,张英,揭育丽,梁伟娟.胃癌患者手术前后血清转化生长因子-α水平对比观察[J].肿瘤防治杂志,2005,12(5):346-347. 被引量:3
  • 2Bogdan S, and Klambt C. Epidermal growth factor receptor signaling. Curr Biol, 2001, 11(8) : R292
  • 3Wakeling AE, Guy SP, Woodbum JR, et al. ZD1839 (Gefitinib) : an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res, 2002, 62(20):5749
  • 4Fumiaki K, Fumihiko K, Yutaka U, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase Ⅰ inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer, 2004, 108(3):464
  • 5Nagahara H, Mimori K, Ohta M, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res, 2005, 11(4) :1368
  • 6Kimura T, Maesawa C, Ikeda K, et al. Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. Oncol Rep,2006,15(5) :1205
  • 7Naruse I, Ohmori T, Ao Y, et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI) IRESSA (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer,2002, 98(2) :310
  • 8Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol, 2005, 23(28) :6829
  • 9Bishop PC, Myers T, Robey R, et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene, 2002, 21(1):119
  • 10Hart SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Gefitinib, ZD1839) in chemotherapy-resistant nonsmall cell lung cancer. Int J Cancer, 2005, 113(1):109

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部